PPAR gamma activation Impact on pathways of clinical care

Slide lecture program (21 slides): View & Download

1. New paradigm of multiple risk factormanagement
2. TRIPOD: Treating insulin resistance reduces incidence of type 2 diabetes
3. TRIPOD & PIPOD: Evidence that insulin resistance causes B-cell failure
4. Anticipated results from large multicenter trials in (pre)diabetes
5. DREAMBackground and study objective
6. DREAMStudy design
7. DREAM: Rosiglitazone prolongs time to occurrence of new-onset diabetes or death
8. DREAM results: Summary
9. TZDs blunt diabetes progression
10. Anticipated results from large multicenter trials in (pre)diabetes
11. CHICAGO: Background and rationale
12. CHICAGO: Study design
13. CHICAGO: Baseline risk factors
14. CHICAGO: Treatment effect on glucose control
15. CHICAGO: Treatment effect on posterior wall mean CIMT
16. CHICAGO: Treatment effect on posterior wall mean CIMT in prespecified subgroups
17. CHICAGO: Summary
18. CHICAGO: Implications
19. Aggressive medical therapy in diabetes
20. Summary: Optimizing outcomes in patients with multiple CVD risks

634919552687955000-Download PPAR section 9 (PPTX 680KB)

PPAR gamma activation Impact on pathways of clinical care	New paradigm of multiple risk factormanagement
TRIPOD:	TRIPOD & PIPOD:
Anticipated results from large multicenter trials in (pre)diabetes	DREAMBackground and study objective
DREAMStudy design	DREAM:
DREAM results: Summary	TZDs blunt diabetes progression
Anticipated results from large multicenter trials in (pre)diabetes	CHICAGO: Background and rationale
CHICAGO: Study design	CHICAGO: Baseline risk factors
CHICAGO: Treatment effect on glucose control	CHICAGO: Treatment effect on posterior wall mean CIMT
CHICAGO: Treatment effect on posterior wall mean CIMT	CHICAGO: Summary
CHICAGO: Implications	CHICAGO: Implications
Aggressive medical therapy in diabetes	Summary: Optimizing outcomes in patients with multiple CVD risks